For countless individuals on the organ transplant waiting list, blood type plays a critical role in their survival. Type O individuals are often dubbed the "universal donors," able to give kidneys to nearly anyone, yet ironically, they can only receive organs from Type O donors. This discrepancy leads to prolonged waiting times for Type O patients, who often see their potential organs allocated to those with Type A or B blood types.
However, a groundbreaking team of researchers has made significant strides in overcoming this challenge by successfully transforming a Type A kidney into a universal Type O kidney. This remarkable feat was demonstrated when the engineered organ was transplanted into a human recipient, showcasing that the body could accept the modified organ without immediate rejection.
"This is the first time we've witnessed this in a human model," stated Dr. Stephen Withers, a professor emeritus of chemistry at the University of British Columbia and a contributor to the research. "It provides us with essential insights into enhancing long-term transplant outcomes."
Innovative Organ Engineering
Blood types are determined by antigens--tiny carbohydrate chains that act like identification markers on blood vessels. When the immune system detects a foreign marker, it triggers an attack.
Typically, to avoid this reaction, doctors must desensitize patients through a process called plasmapheresis, which removes antibodies from the blood. While effective, this method can leave patients vulnerable to infections.
In search of a more refined approach, researchers, including Withers and Dr. Turun Song, discovered a solution involving two specific enzymes derived from bacteria. These enzymes can effectively remove the Type A antigens, creating a Type O "blank slate" kidney.
In the early 2010s, Withers and his colleague Jayachandran Kizhakkedathu focused on developing universal donor blood. Their efforts culminated in 2019 when they identified how certain bacterial enzymes could alter Type A blood into Type O.
"These enzymes are highly active, selective, and effective at low concentrations," explained Dr. Kizhakkedathu. "This made the concept feasible."
Advancing from Blood to Organs
Several research teams took notice of this innovative method. In 2022, a team in Toronto demonstrated that lungs could also be converted. Subsequent tests on blood, lungs, and kidneys showed promising results.
However, no one had attempted to apply this technique in a living human. A recent study finally provided the answer, as researchers successfully transplanted the modified kidney into a brain-dead recipient with family consent, allowing for observation without endangering a life.
Upon attaching the re-coded "Enzyme-Converted O" (ECO) kidney, the results were astonishing: the kidney exhibited a healthy pink color, indicating functionality, and began producing urine--1,300 ml within the first 24 hours--without any signs of immediate rejection.
Nonetheless, the study also highlighted a significant challenge in organ engineering: antigen regeneration. By day three, the kidney cells began to restore their original Type A antigens, prompting the recipient's immune system to recognize the organ as foreign. Biopsies indicated the onset of antibody-mediated rejection (AMR) starting on day four.
Implications of the Research
While this may appear to be a setback, researchers view it as a valuable learning opportunity. They now understand the timing of when the biological disguise begins to fade--approximately 48 hours post-transplant.
The researchers are exploring "maintenance therapy," which may involve administering the A-cleaving enzymes directly to the patient starting on day two, helping to suppress antigen visibility until the organ reaches a stage of "accommodation," where it can naturally resist immune responses.
If successful, this advancement could revolutionize organ transplants for individuals who are currently incompatible due to blood type differences. The ability to "convert" kidneys from deceased donors could dramatically reduce the waiting times for Type O candidates, who presently face a 2 to 4-year longer wait compared to others.
Interestingly, this remarkable innovation traces back to the role of gut bacteria, which may hold the key to expanding the universal donor pool. This complex yet brilliant solution addresses a critical issue that has impacted countless lives.